Nalaganje...
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
BACKGROUND: Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). METHODS: Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles...
Shranjeno v:
| izdano v: | Cephalalgia |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959035/ https://ncbi.nlm.nih.gov/pubmed/27288354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102416652092 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|